Merck & Company Inc (MRK)vsNeoGenomics Inc (NEO)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
NEO
NeoGenomics Inc
$17.32
-1.65%
HEALTHCARE · Cap: $2.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 8587% more annual revenue ($66.57B vs $766.29M). MRK leads profitability with a 4.8% profit margin vs -6.8%. NEO appears more attractively valued with a PEG of 2.09. NEO earns a higher WallStSmart Score of 48/100 (D+).
MRK
Hold36
out of 100
Grade: F
NEO
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+78.2%
Fair Value
$52.45
Current Price
$17.32
$35.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Earnings expanding 130.6% YoY
Reasonable price relative to book value
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Expensive relative to growth rate
Weak financial health signals
ROE of -12.0% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : NEO
The strongest argument for NEO centers on EPS Growth, Price/Book. Revenue growth of 11.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : NEO
The primary concerns for NEO are PEG Ratio, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while NEO is a turnaround play — different risk/reward profiles.
NEO carries more volatility with a beta of 1.75 — expect wider price swings.
NEO is growing revenue faster at 11.2% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
NEO scores higher overall (48/100 vs 36/100) and 11.2% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →NeoGenomics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?